TNF and osteoarthritis: It was found that both TNF-α and adalimumab can permeate out of the affected joint, albeit, at different rates.[11] TNF-α permeation rate may be different in patients with osteoarthritis and the rate of permeation of adalimumab at a lower dose, specifically, 10 mg may be different.